Exercise 18FDG imaging for the detection of CAD: What are the clinical hurdles?

被引：8

作者：

Jain D. ^{[1
]}

He Z.X. ^{[1
]}

Ghanbarinia A. ^{[1
]}

机构：

[1] Nuclear Cardiology Laboratory, Drexel University, College of Medicine, Philadelphia, PA 19102

来源：

Current Cardiology Reports | 2010年 / 12卷 / 2期

关键词：

Ischemia; Myocardial perfusion imaging; PET; SPECT;

D O I：

10.1007/s11886-010-0087-8

中图分类号：

学科分类号：

摘要：

Myocardial perfusion imaging (MPI) has been in clinical use for over 30 years, providing an effective, reliable, and relatively simple tool for diagnosis, risk stratification, and follow-up of patients with suspected or know coronary artery disease (CAD). The unique strength of nuclear imaging is its ability to provide tools for imaging biochemical and metabolic processes, and receptor and transporter functions at molecular and cellular levels in intact organisms under various physiologic conditions. Metabolic imaging using radiolabeled glucose analogues (18F-fluorodeoxyglucose [ 18FDG]) provides a unique ability to image myocardial ischemia directly ("hot spot" imaging) in patients with known or suspected CAD. Exercise 18FDG imaging can potentially overcome some of the limitations of currently used stress-rest MPI. In this article, we describe recent studies using exercise 18FDG for imaging myocardial ischemia and its potential use in routine clinical practice. © Springer Science+Business Media, LLC 2010.

引用

页码：170 / 178

页数：8

共 38 条

[1]

Zaret B.L., Strauss H.W., Martin N.D., Et al., Noninvasive evaluation of regional myocardial perfusion with radioactive potassium: Study of patients at rest, exercise, and during anginal pectoris, N Engl J Med, 288, pp. 809-812, (1973)

[2]

Beller G.A., Zaret B.L., Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease, Circulation, 101, pp. 1465-1478, (2000)

[3]

Jain D., Zaret B.L., Nuclear imaging in cardiovascular medicine, Essentials of Cardiovascular Medicine, pp. 221-244, (2005)

[4]

Jain D., Wackers F.J., Mattera J., Et al., Biokinetics of technetium-99mtetrofosmin: Myocardial perfusion imaging agent: Implications for a one-day imaging protocol, J Nucl Med, 34, pp. 1254-1259, (1993)

[5]

Jain D., Technetium-99 m labeled myocardial perfusion imaging agents, Semin Nucl Med, 29, pp. 221-236, (1999)

[6]

Samady H., Wackers F.J., Zaret B.L., Et al., Pharmacological stress perfusion imaging with adenosine: Role of simultaneous low level treadmill exercise, J Nucl Cardiol, 9, pp. 188-196, (2002)

[7]

Druz R.S., Current advances in vasodilator pharmacological stress perfusion imaging, Semin Nucl Med, 39, pp. 204-209, (2009)

[8]

Boden W., Management of chronic coronary disease is the pendulum returning to equipoise?, Am J Cardiol, 101, (2008)

[9]

Llaurado J.G., The quest of the perfect myocardial perfusion indicator⋯still a long way to go, J Nucl Med, 42, pp. 282-284, (2001)

[10]

Zaret B.L., Pursuit of the ideal perfusion agent, J Nucl Cardiol, 9, pp. 149-150, (2002)

← 1 2 3 4 →